Advertisement
Loading...

BioMark Diagnostics Inc.

BMKDFPNK
Healthcare
Medical - Diagnostics & Research
$0.50
$0.06(14.64%)
U.S. Market opens in 13h 17m
Advertisement

BioMark Diagnostics Inc. (BMKDF) Stock Competitors & Peer Comparison

See (BMKDF) competitors and their performances in Stock Market.

Peer Comparison Table: Medical - Diagnostics & Research Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
BMKDF$0.44+0.09%46.2M-44.00-$0.01N/A
WUXAY$15.94-1.06%45.9B15.63$1.02+1.76%
LZAGF$651.40+4.15%45.5B39.45$16.51+0.49%
WUXIF$15.00+8.07%44.8B14.85$1.01+3.26%
LZAGY$62.81-0.05%44.7B38.05$1.65+0.91%
ERFSF$72.43-2.38%12.4B23.87$2.97+1.19%
BMXMF$84.00+2.84%9.9B21.65$3.88+1.22%
BMXXY$7.91-4.70%9.3B20.28$0.39+1.31%
SKHCF$14.58+21.50%7.2B18.46$0.79+4.98%
SKHHY$13.61+2.18%6.7B17.25$0.79+5.38%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

BMKDF vs WUXAY Comparison May 2026

BMKDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, BMKDF stands at 46.2M. In comparison, WUXAY has a market cap of 45.9B. Regarding current trading prices, BMKDF is priced at $0.44, while WUXAY trades at $15.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

BMKDF currently has a P/E ratio of -44.00, whereas WUXAY's P/E ratio is 15.63. In terms of profitability, BMKDF's ROE is -1.53%, compared to WUXAY's ROE of +0.27%. Regarding short-term risk, BMKDF and WUXAY have similar daily volatility (0.00).Check WUXAY's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions